Search for a poster by keyword
Clinical Evaluation of human embryonic stem cells (hESCs) induced with directed differentiation to gonadotrope cells to cure vasculogenic impotency and to improve coital frequency in males. An open st
Timothy S. Andersson, David K. Chin, Wendy Hiu Wai Wong. University Hospital Malmo Sweden, Stanford Biomed, Inc. Stanford, California, USA, Syed Skin Care, Inc. San Francisco, California, USA
This work demonstrates the clinical efficacy, tolerability and safety of patient-syngenic hESC induced with directed differentiation to gonadotrope cells. Hypothalamus transmits gonadotropin releasing factor to pituitary that sets off LH and FSH to Sertoli cell and Seminiferous tubule resulting Leydig cell to produces testosterone. This potential offers a rationale to evaluate hESCs to cure patients with vasculogenic impotency and to improve coital frequency in males.
Five noncovalent peptidic ligands show different affinity rankings in solution and gas phase
Andrey Dyachenko , Michael Goldflam , Marta Vilaseca , Ernest Giralt . Institute for Research in Biomedicine (IRB), Barcelona Science Park, University of Barcelona, Spain
Stability of noncovalent complexes of VEGF protein with 5 peptidic ligands is studied. Experiments were conducted in solution (NMR CSP, ITC) and in gas phase (CID TOF MS). Each ligand differs from others in chirality of one amino acid. It was shown, that trend of stability of the studied noncovalent complexes is reversed in the gas phase relatively to the solution. An explanation of this behavior is presented.
Development of a Bone Marrow Targeting Cell Therapy
Thomas Kean*, Lori Duesler*, Tambet Teesalu**, Erkki Ruoslahti**, James E Dennis*. *Case Western Reserve University, Cleveland, Ohio, ** Burnham Institute for Medical Research at University of California, Santa Barbara, California
One major obstacle in stem cell therapy is poor cell engraftment. To address this issue, concurrent investigations were made to develop novel peptides targeting bone marrow and a method to transiently ‘paint’ targeting molecules onto cells. Painting was studied using a model palmitated peptide. Novel bone marrow targeting peptides were sought using in vivo phage display in a locally irradiated mouse model that has an internal control (untreated leg).
Transfecting Small Molecules, Peptides
Van Q., Atze K., Litzenberger D., Ackerstaff J.T., Strübing Y., Yolcu D., Franke S.,Mobbs K.J. and Kazinski M.. amaxa AG, Nattermannallee 1, 50829 Köln, Germany
The Nucleofector® Technology enables efficient and reproducible transfection of primary cells and cell lines at throughputs of up to 96 samples per run. Nucleofection® now extends its range of application to deliver small molecules substrates and protein substrates such as
peptides, proteins and antibodyconjugates.
A Novel Fluorimetric Assay for the Detection of TACE (a-Secretase)
Vera Rakhmanova, Xudong Zhu, Fengying Li, Xiaofen Zhong, Anita Hong and Xiaohe Tong. AnaSpec, Inc.
To facilitate high throughput screening of TACE inhibitors, AnaSpec synthesized a novel peptide substrate for TACE using QXL™ 520/5-FAM FRET pair. Using this FRET substrate, AnaSpec developed a new kit – the SensoLyte™ 520 TACE Activity Assay. This kit can be used to detect the activity of the enzyme and for screening of TACE inhibitors. It is highly sensitive and can detect subnanogram amounts of enzyme.
Involvement of enkephalins and delta-opioid receptors in the expression of levodopa-induced dyskinesia in a model of hemiparkinsonian rat
Fabrice Billet, Jean Costentin & Nathalie Dourmap. Laboratory of Experimental Neuropharmacology
This study was performed to test the involvement of d-opioid receptors in dyskinesia induced by L-DOPA in hemiparkinsonian rats. Our results indicate that endogenous enkephakins modulate the expression of L-DOPA-induced dyskinesia. It also appears that d-opioid receptors located on corticostriatal terminals could be involved in the development of these dyskinesia. These results confer on d-opioid antagonists interesting properties in the improvement of Parkinson’s disease therapy.
1 - 6 of 24 Next